昱展新藥生技股份有限公司
昱展新藥生技股份有限公司為藥物研發公司，專注於開發中樞神經系統 (CNS) 疾病與慢性病的長效釋放藥物。開發中的 ALA-1000 用於治療鴉片類藥物成癮；臨床前管線包括用於帕金森氏症的 ALA-4000、治療難治型憂鬱症的 ALA-3000 及治療精神分裂症的 ALA-5000。公司成立於 2016 年，總部位於台灣台中市。
該股 RSI(6) 為 56.0，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日均線，跌破60日、120日均線。KD 指標中性（K=46.3）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -4 | 0 | +2 | -3 |
| 09-23 | -4 | 0 | 0 | -4 |
| 09-22 | +15 | 0 | +2 | +14 |
| 09-21 | +2 | 0 | 0 | +2 |
| 09-18 | -36 | 0 | +3 | -36 |
| 09-17 | +48 | 0 | 0 | +48 |
| 09-16 | +9 | 0 | +1 | +9 |
| 09-15 | +14 | 0 | 0 | +14 |
| 09-14 | +2 | 0 | +2 | +2 |
| 09-11 | -5 | 0 | +2 | -5 |
| 09-10 | +9 | 0 | +2 | +10 |
| 09-09 | +34 | 0 | 0 | +34 |
| 09-08 | +10 | 0 | 0 | +10 |
| 09-07 | +9 | 0 | +2 | +10 |
| 09-04 | +12 | 0 | 0 | +12 |
| 09-03 | +5 | 0 | +2 | +5 |
| 09-02 | +15 | 0 | +2 | +15 |
| 09-01 | -18 | 0 | +5 | -18 |
| 08-31 | -20 | 0 | +4 | -20 |
| 08-28 | -25 | 0 | +2 | -25 |
| 08-27 | -8 | 0 | 0 | -8 |
| 08-26 | +30 | 0 | 0 | +30 |
| 08-25 | -16 | 0 | 0 | -18 |
| 08-24 | -6 | 0 | 0 | -6 |
| 08-21 | +3 | 0 | +4 | +5 |
| 08-20 | +50 | 0 | 0 | +50 |
| 08-19 | -13 | 0 | 0 | -13 |
| 08-18 | +33 | 0 | +2 | +34 |
| 08-17 | +10 | 0 | 0 | +10 |
| 08-14 | -5 | 0 | +1 | -5 |
| 08-13 | +16 | 0 | 0 | +16 |
| 08-12 | +6 | 0 | +2 | +4 |
| 08-11 | +4 | 0 | +1 | +3 |
| 08-10 | +17 | 0 | +5 | +19 |
| 08-07 | 0 | 0 | 0 | 0 |
| 08-06 | +6 | 0 | 0 | +6 |
| 08-05 | +10 | 0 | 0 | +10 |
| 08-04 | +10 | 0 | 0 | +10 |
| 08-03 | -2 | 0 | 0 | -3 |
| 07-31 | -20 | 0 | +4 | -18 |
| 07-30 | -8 | 0 | +14 | -7 |
| 07-29 | +124 | 0 | +8 | +124 |
| 07-28 | -4 | 0 | +2 | -4 |
| 07-27 | +12 | 0 | 0 | +12 |
| 07-24 | -4 | 0 | 0 | -5 |
| 07-23 | +8 | 0 | +2 | +9 |
| 07-22 | +1 | 0 | 0 | +1 |
| 07-21 | +17 | 0 | 0 | +17 |
| 07-20 | +22 | 0 | 0 | +22 |
| 07-17 | -30 | 0 | +4 | -31 |
| 07-16 | +4 | 0 | 0 | +4 |
| 07-15 | +2 | 0 | +2 | +3 |
| 07-14 | -6 | 0 | 0 | -7 |
| 07-13 | -3 | 0 | 0 | -4 |
| 07-09 | +3 | 0 | 0 | +3 |
| 07-08 | -73 | 0 | +1 | -75 |
| 07-07 | -79 | 0 | +22 | -75 |
| 07-06 | -18 | 0 | +1 | -18 |
| 07-03 | +5 | 0 | 0 | +5 |
| 07-02 | -19 | 0 | 0 | -19 |
| 07-01 | +26 | 0 | 0 | +26 |
| 06-30 | -24 | 0 | +2 | -24 |
| 06-29 | +28 | 0 | 0 | +28 |
| 06-26 | +12 | 0 | 0 | +12 |
| 06-25 | +4 | 0 | 0 | +3 |
| 06-24 | +5 | 0 | 0 | +5 |
| 06-23 | 0 | 0 | +3 | -1 |
| 06-22 | -6 | 0 | 0 | -7 |
| 06-18 | -4 | 0 | +4 | -2 |
| 06-17 | -28 | 0 | +8 | -25 |
| 06-16 | +2 | 0 | 0 | +2 |
| 06-15 | -3 | 0 | 0 | -3 |
| 06-12 | +33 | 0 | +2 | +34 |
| 06-11 | +10 | 0 | +2 | +10 |
| 06-10 | -27 | 0 | 0 | -27 |
| 06-09 | -39 | 0 | +4 | -38 |
| 06-08 | +9 | 0 | +2 | +7 |
| 06-05 | +1 | 0 | 0 | +1 |
| 06-04 | -14 | 0 | +2 | -13 |
| 06-03 | +14 | 0 | +4 | +14 |
| 06-02 | -34 | 0 | +4 | -34 |
| 06-01 | -28 | 0 | 0 | -28 |
| 05-29 | +20 | 0 | 0 | +20 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 0 | -100.0% | - |
| 2026/03 | 25 萬 | - | - |
| 2026/02 | 0 | - | - |
| 2026/01 | 0 | -100.0% | - |
| 2025/12 | 100 萬 | - | - |
| 2025/11 | 0 | -100.0% | - |
| 2025/10 | 50 萬 | - | - |
| 2025/09 | 0 | - | -100.0% |
| 2025/08 | 0 | - | - |
| 2025/07 | 0 | - | - |
| 2025/06 | 0 | -100.0% | - |
| 2025/05 | 125 萬 | - | - |